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Abstract
Background—In 1995 the Tucson Children’s Respiratory Study (TCRS) identified clinically
distinct phenotypes amongst early wheezers; the Avon Longitudinal Study of Parents And
Children (ALSPAC) has recently re-examined these.
Objectives—To validate statistically derived ALSPAC phenotypes in the Southampton
Women’s Survey (SWS) using infant and 6 year lung function, and allergic sensitisation at 1, 3
and 6 years, comparing these with TCRS phenotypes.
Methods—Complete 6 year follow-up data were available for 926 children, selected from 1973
infants born to 12,579 women characterised pre-conception. 95 children had V’maxFRC and
FEV0.4 measured age 5-14 weeks using rapid compression/raised volume techniques. At 6 years
we performed spirometry (n=791), fractional exhaled nitric oxide (FeNO, n=589) and
methacholine challenge (n=234). Skin prick testing was performed at 12m, 3 and 6 years (n=1494,
1255, 699, respectively). Using wheeze status questionnaire data at 6m, 12m, 2, 3 and 6 years we
classified children into TCRS (never, transient early, persistent, late-onset) and ALSPAC based
groups (never, early, transient, intermediate-onset, late-onset, persistent).
Results—Amongst ALSPAC groups, persistent and late-onset wheeze were associated with
atopy at 3 and 6 years, whilst intermediate-onset wheeze showed earlier atopic association at 1
year; all three were associated with FeNO at 6 years. Persistent wheezers had lower infant
(V’maxFRC p<0.05) and 6 year lung function (FEV1, FEV1/FVC and FEF25-75, p<0.05), whilst
late and intermediate-onset wheezers showed no lung function deficits. Transient wheezers were
non-atopic but showed persistent lung function deficits (V’maxFRC in infancy, FEV1 and
FEF25-75 at 6 years, all p<0.05). Those who wheezed only in the first year (early phenotype)
showed no lung function deficits. No associations were seen with 6 years bronchial hyper-
responsiveness or infancy FEV0.4.
Conclusion—SWS cohort data validates the statistically derived ALSPAC 6-class model. In
particular, lung function and atopy successfully differentiate persistent, late-onset and
intermediate-onset wheeze, whilst the Tucson ‘transient early’ wheeze phenotype can be sub-
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classified into groups that reflect early lung function. Since the 4-class model fails to adequately
differentiate phenotypes based on lung function and atopy, we propose that strong consideration
be given to using the 6-class paradigm for longitudinal outcome work in wheezing with onset in
early life.
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Wheeze; asthma; phenotype; lung function; cohort; atopy
INTRODUCTION
Wheezing in infancy is common, however only a small proportion of these children will
continue to wheeze into later childhood and beyond. A number of studies have attempted to
classify wheezing pre-school children into different phenotypes in order to assist
investigation of the pathways of asthma development. The Tucson Children’s Respiratory
Study (TCRS) published the first classification according to wheezing status up to 6 years of
age[1]. TCRS characterised children into 4 groups, namely never wheezed, transient early
wheeze, late wheeze and persistent wheeze; persistent and late-onset wheeze were
associated with atopy, however transient early wheeze was not, as confirmed by further
studies using this classification [2-5]. TCRS found persisting lung function deficits in those
with transient wheeze, suggesting this was a phenomenon of small airways, with resolution
of wheeze once airway calibre improves with growth, albeit without returning to normal[1].
Whilst TCRS found that persistent wheezers did not have lung function deficits at birth, the
Copenhagen Prospective Studies on Asthma and Childhood (COPSAC) cohort of at-risk
children did find diminished lung function shortly after birth in those with asthma at 7
years[6] and the authors hypothesized that perhaps TCRS had been underpowered to find
this statistical difference. Likewise, Turner et al found lung function deficits that preceded
the development of asthma [7]. A cohort from Perth, Australia performed longitudinal lung
function testing, comparing VmaxFRC at birth and FEF25-75 at 4-6 years and 11 years. They
found that transient wheezers (wheeze at 0-3 years) had the best lung function of all groups
at birth, but this diminished over time with reference to other groups, supporting the idea
that transient wheeze is associated with ongoing lung function deficits beyond the
symptomatic period. Development of late and persistent wheeze has been associated with
reduced airway function interacting with atopic sensitisation, immune dysregulation and
airway remodelling, in line with the classical view of asthma pathogenesis[8-11]. It is
possible that persistent wheezers represent an overlap between these theories of transient
wheeze and more typical asthma pathogenesis with later resolution of wheeze by puberty in
those who are not atopic[4].
The Tucson phenotype classification does not, however, fully describe the heterogeneity
amongst wheezing children and attempts have been made to reclassify these phenotypes.
The Avon Longitudinal Study of Parents And Children (ALSPAC) used longitudinal latent
class analysis (LLCA) to redefine the wheezing phenotypes purely on statistical grounds,
independent from any preconceived bias of the clinician. Amongst 6265 children followed-
up to 6 years of age they identified six classes of pre-school wheeze; never/infrequent,
transient early, prolonged early, intermediate onset, late onset and persistent [12]. They then
replicated the process with 2810 children from the Prevention of Infant Asthma and Mite
Allergy (PIAMA) cohort and 5760 from ALSPAC up to 8 years of age[13]. The replication
identified 5 classes of wheezing children; never, transient early, intermediate onset, late
onset and persistent. The intermediate onset, late onset and persistent phenotypes were
strongly associated with atopy, with the strongest association seen amongst the intermediate-
onset phenotype. All wheezing groups showed poorer lung function at 8 years, including
transient early wheezers who were, by definition, no longer wheezing by this time. The
Collins et al. Page 2
Pediatr Pulmonol. Author manuscript; available in PMC 2014 January 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
transient early wheezers did not, however, show greater bronchial hyper-responsiveness
(BHR) compared to those who never wheezed. These findings suggest there is a distinct
intermediate-onset phenotype not captured in the TCRS classification and reinforces the
suggestion that transient early wheezers have ongoing diminished lung function without
persisting symptoms of reactive airways. It is this latter group that may be at increased risk
of chronic obstructive pulmonary disease (COPD) in later life owing to continued poor lung
function[14,15]. A recent application of latent class growth analysis, which differs slightly
from LLCA, in the Columbia Children’s Centre for Environmental Health (CCEH) cohort of
African-American and Latino children identified 4 classes that were similar to those in the
TCRS study[16]. Spycher et al also used LLCA in 1650 UK children, identifying 3
phenotypes of wheeze and 2 phenotypes of cough[17].
We hypothesised that the statistically derived ALSPAC 6-class model could be validated
using longitudinal lung function and atopic sensitisation data from the first 6 years of life.
METHODS
Participants were mother-child pairs from the Southampton Women’s Survey; a cohort study
with the objective, among others, of studying early life environmental influences on child
growth and development, including respiratory disease and asthma in childhood[18]. During
the period 1998-2002, 12,579 women aged 20-34 were recruited through their GP surgeries
prior to conception. There were 1973 births before the end of 2003. Those born before 35
weeks and/or twins were excluded from the study and only one child per SWS mother was
included. As previously described[19] a subset of 150 infants born to the SWS women had
lung function measured at 5-14 weeks postnatally, with 95 of these having a complete set of
data to 6 years. Child follow-ups were conducted at 6 months (n=1896), 12 months
(n=1840), 2 years (n=1735), 3 years (n=1640) and 6 years (n=940) through home visits or
attendance at clinic. The 6-year follow-up was performed during 2006-2010 and of the 1523
babies born between February 2000 and June 2003, 940 had questionnaire data from a
home-visit and 791 had spirometry performed. Figure 1 shows the numbers at each follow-
up stage and the numbers who had lung function/skin prick testing. Parental consent was
obtained and ethics approval was granted by the Southampton and South West Hampshire
Local Research Ethics Committee (LREC Number 276/97, 307/97, 089/99, 125/98 and 06/
Q1702/104).
Atopy
Atopy was defined as any allergen response ≥ 3 mm against cat, dog, house dust mite
(Dermatophagoides pteronyssinus), grass pollens, egg and milk allergens (Hollister-Stier,
Spokane, WA) at ages 1 (n=1494) and 3 years (n=1255). At 6 year follow-up (n=699), tree
pollen was added (ALK Abelló Hørsholm, Denmark). Readings were considered valid only
in the presence of appropriate positive and negative control responses.
Airway inflammation
Exhaled nitric oxide (FeNO) was measured with a NIOX® chemiluminescence analyser
(Aerocrine, Sweden) at a controlled expiration of 50ml/sec, by trained research nurses. The
technique used was in line with the ERS/ATS recommendations[20] and a mean value was
calculated from three readings where possible. FeNO data were normalised using an inverse
square root transformation then standardised as a z-score. The sign of the values was
reversed so that high untransformed FeNO values gave rise to high standardised scores.
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Allocation to wheeze phenotype groups
The ISAAC core questionnaire wheezing module was delivered by research nurses[21].
Mothers were asked at each visit whether their child had experienced ‘episodes of chestiness
associated with wheezing or whistling in his/her chest in the last 12 months’. Using wheeze
data collected in the first year, at 2/3 years, and at 6 years old, the children were grouped
into both the Tucson[1]; never, transient early, late, persistent groups, and ALSPAC based
phenotypes[13]; never, early, transient, intermediate-onset, late-onset, and persistent
wheeze. Our ‘early’ and ‘transient’ groups were so named in order to differentiate them
from the Tucson ‘transient early’ group and be roughly equivalent to the ALSPAC ‘transient
early’ and ‘prolonged transient’ groups[12]. Table 1 shows how the children were classified
into the wheezing phenotypes using the questionnaire data from 6m, 12m, 2 years, 3 years
and 6 years, and how our naming of groups corresponds to the ALSPAC phenotypes.
Children who wheezed in the first year and at 6 years but not in between were classified as
persistent wheezers, in line with the ALSPAC/PIAMA LLCA allocations [13], however we
acknowledge that these could be children who are a combination of the early and late-onset
groups.
Lung function
In Infancy—As previously described[19] infant lung function measurements were obtained
during quiet sleep augmented by oral chloral hydrate (75-100mg/kg). V’maxFRC was
measured using rapid thoracic compression (RTC) during tidal breathing using an inflatable
jacket and a leak-free facemask with Fleisch pneumatachograph (Dynasciences, Blue Bell,
CA). RTC from a raised volume manoeuvre was used to calculate FEV0.4. Data were
collected in RASP software (Physiologic Ltd, Newbury, Berks, UK), with SQUEEZE
software (Paul Dixon, London, UK) used to analyse the flow-volume curves and calculate
FEV0.4. V’maxFRC and FEV0.4 were corrected for age at test but not for size[19].
At age 6 years—Spirometry was performed according to ATS/ERS guidelines[20] but
without noseclips. Experienced research nurses used a portable Koko spirometer and
incentive software (KoKo version 4; PDS Instrumentation; Louisville, USA) to record flow-
volume loops. FEV1, FEV1/FVC and FEF25-75 were corrected for height and gender, and
expressed as percent predicted[22].
Bronchial hyper-responsiveness (BHR) testing was performed according to ATS/ERS
guidelines[20] using dosimeter administered methacholine (Koko; PDS Instrumentation;
Louisville, USA) via an air-driven nebuliser (Sidestream®; Respironics, UK). Methacholine
doses ranged from 0.06 mg/ml to 16 mg/ml with termination at either the upper
concentration or a 20% fall in FEV1. Data were transformed using the formula
Log.slope=100/[regression slope of FEV1 drop and log10(cumulative methacholine dose) +
10] in order to remove negative values and produce a normal distribution of the variable,
with a lower value indicating greater responsiveness.
Statistical Analysis
Using STATA/SE 11.0, Poisson regression with robust variance was performed for atopic
sensitisation outcomes[23] giving the relative risk of atopy for each wheeze group at 1,3 and
6 years of age compared to those who never wheezed.. Linear regression was used for lung
function outcomes, within which the following were assessed for potential confounding and
included in the analysis if significantly correlated with the outcome and exposure; maternal
asthma, smoking in pregnancy, smoke exposure in 1st year and 6th year of life, gestation,
birth weight, birth weight z score (adjusted for gestation), sex, parity, maternal atopy, pets in
the home, breastfeeding duration, social class, maternal education and month of birth. This
is in line with recent published recommendations for confounders in studies of childhood
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asthma[24]. The prevalence of the potential confounders for each of the ALSPAC and
TCRS groups can be found in supplementary table 5 and 6. Infant lung function, BHR and
FeNO required log transformation to normalise and therefore they are presented as ratios of
geometric means, which provides consistency with the presentation of the ALSPAC
data[13].
RESULTS
Study population
A total of 1840 (92.6%) children were seen at 1 year, 1735 (87.3%) at 2 years, 1640 (82.5%)
at 3 years and 940 (47.3%) at 6 year follow up (Figure 1). Children were more likely to have
complete follow-up to 6 years if they were higher social class, had more highly educated
parents, or were exposed to lower rates of smoking, as shown in supplementary table 1.
There were no important differences in participants with spirometry in the 6-year follow-up
versus those without and those with infant lung function versus those without
(supplementary tables 2 and 3). The differences between those with follow-up and those
without were included in our analysis as potential confounders (tables E4, E5 and E6). Table
2 shows the number of children in each phenotype who contributed spirometry, BHR, FeNO
and skin test results data. There were small numbers with infant lung function data in the
intermediate-onset (n=4), late-onset (n=1) and persistent groups (n=5). This was also true for
BHR testing; intermediate n=17, late n=4 and persistent n=17.
Wheeze phenotypes in SWS
Using the Tucson and ALSPAC phenotypes, this SWS cohort had 417 TCRS early transient
wheezers (161 ALSPAC early and 256 ALSPAC transient) and 116 TCRS persistent
wheezers (57 ALSPAC intermediate-onset and 59 ALSPAC persistent) with 20 late-onset
wheezers (same definition in ALSPAC and TCRS) (Figure 2).
Lung function in infancy and childhood
Lower infant lung function (V’maxFRC) was seen in ALSPAC and TCRS transient groups
(p<0.05) and in the ALSPAC persistent (p<0.05) but not the TCRS persistent wheeze groups
(Table 3). No association was seen between infant FEV0.4 and any phenotype.
The ALSPAC transient group showed statistically lower lung function persisting to 6 years
with a mean FEF25-75 of 95.1% predicted and FEV1 of 100.3% predicted (both p<0.05)
versus 101.0% and 103.1% respectively for the never wheezed group (table 3 and figure 3).
The ALSPAC persistent group showed significantly lower 6 year FEF25-75 (mean 84.9%,
p<0.001), FEV1 (97.3%, p<0.05) and FEV1/FVC (95.5%, p<0.05) whilst the TCRS
persistent group also showed significantly lower in FEF25-75 (89.5%, P<0.001), FEV1
(99.0%) and FEV1/FVC (97.1%, all p<0.05). The TCRS transient early group (including
both ALSPAC early and transient groups) showed only reduced FEF25-75 at 6 years (96.7%,
p<0.05). Intermediate-onset and late-onset groups had similar lung function in infancy and
at 6 years to the non-wheeze group.
No associations were seen between BHR and any of the wheeze phenotypes. Infant and 6
year lung function parameters were converted to z scores to enable tracking over time
(figures 3a and 3b). When compared to others in our cohort, persistent wheezers’ z scores
for our lung function parameters remain below all other groups. Although the transient
wheeze group are below the other groups (except persistent) in infancy, there is some
improvement by age 6 relative to other wheezing groups. They do, however remain below
intermediate and late-onset groups despite the fact these two groups are now symptomatic
and transient wheezers are not.
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Atopy in infancy and childhood
None of the groups that had ceased wheezing by 6 years of age showed an increased risk of
atopy at 1, 3 or 6 years of age (table 4, figure 3). Intermediate-onset wheezers showed an
increased risk for atopy at all ages with relative risks of 3.3, 3.0 and 2.9 at 1, 3 and 6 years
(all p<0.001), however late-onset and persistent wheezers did not show an increased risk of
atopy until 3 years of age (late - RR 2.5 at 3 and 6 years, p<0.05, persistent - RR 2.4 and 2.0
at 3 and 6 years respectively, p<0.05). These RR are shown across the three ages in figure
3c. TCRS groups show a different pattern (table 4). TCRS persistent wheeze showed an
increased risk for atopy at all ages (RR 2.6 at 1yr, p<0.05, 3.2 at 3yr and 2.6 at 6yrs, both
p<0.001). It should be noted that the TCRS persistent group would include the ALSPAC
intermediate-onset wheezers that showed atopic sensitisation at all ages.
Exhaled nitric oxide showed the same pattern of association as atopy at 6 years, being
significantly associated with intermediate, late and persistent wheeze (all p<0.001) and
significantly associated with atopy at 6 years in all children (p<0.001) (table 4).
DISCUSSION
The ALSPAC phenotypes [12] which were statistically derived based on symptoms, have
successfully been validated using longitudinal lung function and atopic sensitisation data
from the SWS cohort. This study, which included measurements not available within
ALSPAC including infant lung function, FeNO at 6 years and 1 year atopy data, not only
confirms that these phenotypes are real, but also provide insight into the underlying
pathophysiology of each phenotype. In particular, among those who are transient early
wheezers, there appear to be physiologic differences between those who wheeze only in the
first year and those who wheeze beyond the first year but have stopped wheezing by age 6.
Atopy was manifested quite early (by age 1) in subjects with intermediate onset wheeze, and
by age 3 in those with late onset and persistent disease. This lends further weight to the
existence of separate late and intermediate-onset phenotypes and supports the hypothesis
that persistent wheeze is an interplay between diminished lung function from birth and
development of atopic sensitisation[4,25].
ALSPAC did not have FeNO data[12], and our data have been able to show that wheeze at 6
years is not only associated with skin sensitisation but also with FeNO which is an indirect
estimate of lower airway eosinophilic inflammation. We have also shown that those who
wheeze only in the first year of life appear distinct from other ‘transient’ wheezing groups,
in that they show no lung function deficits in infancy or childhood and are perhaps similar to
children in the never/infrequent wheeze group.
In keeping with previous studies[1,6] we found that, when compared to children who have
never wheezed, children with transient wheeze outside the first year are more likely to have
persistently lower lung function even when symptoms have resolved. In contrast to the
ALSPAC/PIAMA [13] and TCRS studies [1], the intermediate onset and late onset groups
did not show significantly diminished lung function at 6 years compared to those who never
wheeze. It may be that greater numbers in these previous studies gave the power to detect
small differences.
It is widely accepted that transient early wheeze may be related to small airways [1], with
improvement in wheeze as the child grows; however the pathogenesis is clearly more
complex than this. By separating the TCRS ‘transient early’ wheeze into ALSPAC ‘early’
(wheeze only in the first year) and ‘transient’ wheeze, differing associations were seen.
Early wheeze was not associated with diminished lung function or atopy, whilst the
remainder of the transient wheezers showed diminished infant lung function (V’maxFRC)
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with persistence of these deficits up to 6 years (FEF25-75 and FEV1), at which time they
were, by definition, asymptomatic. This is in keeping with the theory that transient wheeze
is a product of reduced airway calibre that improves with age, such that children are no
longer symptomatic but still have minor deficits in lung function. Since persistent wheeze
was not significantly associated with atopy at 1 year, this group may reflect a larger group of
those with diminished lung function at birth that either cease to wheeze with growth
(transient wheeze), have such diminished airway function that they fail to grow out of
wheeze by 6 years (persistent non-atopic wheeze) or develop atopic sensitisation that leads
to persistent wheezing at 6 years (classical asthma). It is possible that the ‘early’ wheezers
have normal airways but an altered immune response to early viral infections that manifests
as wheeze in the first year of life but improves as the immune system matures. Since there
was no significant difference in month of birth between the early group and the never
wheezers or transient wheezers (data not shown), this does not simply reflect a seasonal
effect of increased respiratory tract infections. ALSPAC had classified children into a never/
infrequent group [12] and our ‘early’ phenotype may correspond more closely to this group,
differentiating them from those who wheeze as a result of poor lung function and possibly
reflecting a difference between bronchiolitis and viral-induced wheeze. It is possible that the
PIAMA LLCA analysis, which found a 5-class model to be optimal, had included these
children within the never/infrequent group [13] and that our infant lung function data
allowed identification of this extra class. The existence of this early group suggests that
many of those who wheeze only in the first year of life do not do so as a result of
significantly altered lung function. This is in contrast to the theory suggested by Young et al
who found that those who wheezed only in the first year of life had impaired lung function
that resolved by 12m of age, whereas wheezing through the first 2 years or in year 2 only
was associated with persisting lung function deficits [11]
Our findings differ from ALSPAC/PIAMA as they found that all wheeze groups had
significantly lower FEV1 at 8 years, whereas our intermediate and late groups did not show
any significant difference from those who never wheezed. This is most likely a reflection of
the greater power in their studies and may also be why we did not show lung function
deficits in the intermediate/late groups prior to the onset of wheeze, as previously suggested
by the Aberdeen cohort [7] and COPSAC [6]. Like the Perth cohort[26], we found
significantly reduced lung function in persistent wheezers both shortly after birth and at 6
years, but, unlike them, we found transient wheezers had diminished lung function shortly
after birth as well. We had the benefit of greater numbers in this wheeze group and, in line
with the original TCRS infant lung function findings, our results likely reflect a significant
difference in lung function at birth in transient wheezers. Our findings that wheeze at school
age was related to atopic sensitisation reinforces the findings of the German Multicentre
Allergy Study (MAS), a birth cohort of 1314 healthy children, who found that persistence of
wheezing through school years was related to development of atopy[4].
Strengths of this study are its infant lung function data, exhaled nitric oxide measurements
and longitudinal atopic sensitisation data. In particular, other cohorts have not included 1
year allergic sensitisation data. Together, these data allow tracking of lung function and
onset of atopy in relation to different wheeze phenotypes. A particular limitation of our
study is the small numbers of children who had infant lung function and were wheezing at 6
years of age. This lack of power may explain the absence of association between wheeze
phenotypes and FEV0.4 in infancy (figure 3). Similarly, there was a surprising lack of
significant association with bronchial hyper-responsiveness at 6 years in children who were
wheezing at 6 years. Again, lack of power is likely to be an issue as there were few children
with BHR data in the intermediate (n=17), late (n=4) and persistent groups (n=17). A
planned meta-analysis of cohort data may overcome this problem. As with most cohort
studies of this type, there was a tendency for children of higher social class to attend follow-
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up; however we controlled for associated confounders (maternal smoking in pregnancy and
during childhood, education and social class) in our analysis. There were also differences
between SWS and ALSPAC in wheezing time points used to classify the phenotypes with
ALSPAC having data from 6m, 12m, 18m 30m, 42m, 54m, 69m and 81m. Rather than map
our follow-up time points to these, we used the phenotype tracking figure that arose from
their analysis and fitted our data to this graph[12]. Also, the 6 year lung function outcomes
showed lung function that was statistically significantly lower in transient and persistent
wheezers, however when expressed as percent predicted they are still within the expected
normal range. This means that the differences are potentially important on a population level
but may not be clinically significant in the individuals.
Many studies have attempted to identify risk factors for asthma/wheeze including fetal/
postnatal growth parameters[27,28], genetics[29-33] and infant lung function[7,26,34], with
varying results. It is only by understanding the wheeze phenotypes that these relationships
can be better elucidated and the diluting effects of grouping wheeze together in a small
number of categories can be overcome. Table 3 shows how some significant associations are
lost by analysing the children according to the broader Tucson phenotypes including failure
to delineate the intermediate-onset group, failure to show infant lung function deficits in the
persistent group and lack of diminished FEV1 at 6 years in the transient wheezers. There is
now good evidence that COPD and all-cause mortality in later life is related to airway
function in childhood[14,15,35,36] and this may be related to wheeze phenotype[37]. Since
infant lung function is impractical in most wheezing children, it is wheeze phenotype,
particularly our transient wheeze group, that may provide information about later risk of
asthma/COPD and risk of mortality from a wide range of causes.
In conclusion, using longitudinal lung function and atopic sensitisation data, the SWS cohort
has not only validated the statistically derived ALSPAC phenotypes of childhood wheeze,
but has also provided insights to the underlying pathophysiology. Our findings confirm the
existence of an ‘intermediate-onset’ phenotype that is similar to late-onset wheeze but has
earlier atopic sensitisation. The SWS cohort demonstrates the utility of separating the
‘transient early’ wheeze group, by considering those who wheeze in their first year only as a
separate group.. We suggest that future research should focus on a 6-class model of early
childhood wheeze. Further work is needed to investigate whether the group of children who
only wheeze in the first year of life reflect a separate phenotype or can be considered
alongside those who never wheeze and thus a 5-class model may be appropriate class model
of early childhood wheeze.
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Abbreviations
SWS Southampton Women’s Survey
TCRS Tucson Children’s Respiratory Study
ALSPAC Avon Longitudinal Study of Parents and Children
PIAMA Prevention of Infant Asthma and Mite Allergy
FEV0.4 Forced Expiratory Volume in 0.4 second
FEV1 Forced Expiratory Volume in 1 second
FEF25-75 Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity
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FVC Forced Vital Capacity
V’maxFRC Maximal Forced Expiratory Flow at Functional Residual Capacity
FeNO Fractional exhaled Nitric Oxide
BHR Bronchial Hyper-responsiveness
COPD Chronic Obstructive Pulmonary Disease
CCCEH Columbia Children’s Centre for Environmental Health
LLCA Longitudinal Latent Class Analysis
LCGA Latent Class Growth Analysis
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Figure 1.
Diagram showing numbers in follow-up groups at each age and number who had skin prick
testing and lung function measurements.
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Figure 2.
Venn diagram showing distribution of children amongst Tucson groups (black circle) and
ALSPAC groups (grey circles)
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Figure 3.
Graph showing tracking of internal z scores for each ALSPAC phenotype for a) maximal
flow at functional residual capacity (V’maxFRC) in infancy and forced expiratory flow at
25-75% vital capacity (FEF25-75) at 6 years of age, b) forced expiratory volume in 0.4
seconds (FEV0.4) in infancy and forced expiratory volume in 1 second (FEV1) at 6 years of
age and c) tracking of relative risk (RR) of atopy at 1, 3 and 6 years.
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Table 1
Assignment of children to phenotypes according to wheezing data at 6 and 12 months, and at 2, 3 and 6 years.
Name of
phenotype
(ALSPAC name
if different)
Wheeze at 6m and/or
12m data
Wheeze at 2yr and/or
3yr data Wheeze at 6 years
ALSPAC phenotypes
Never
(never/infrequent) No No No
Early
(transient early) Yes No No
Transient
(prolonged early) Yes/No Yes No
Intermediate No Yes Yes
Late No No Yes
Persistent Yes Yes/No Yes
Wheeze at any time at 6m, 12m, 2yr or 3 yr Wheeze at 6 years
Tucson phenotypes
Never No No
Transient Early Yes No
Late No Yes
Persistent Yes Yes
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Table 4
Relative risk of atopy versus no atopy at 1yr, 3yrs and 6yrs according to phenotype with 95% confidence
interval in brackets. Each phenotype compared to never wheezed. Poisson regression with significant
associations shown in bold.
Phenotype RR for atopy at 1year
RR for atopy at 3
years
RR for atopy at 6
years
ALSPAC
Never 1(reference)
1
(reference)
1
(reference)
Early 0.97(0.50-1.87)
0.93
(0.55-1.59)
1.31
(0.89-1.95)
Transient 1.15(0.66-2.02)
1.07
(0.66-1.71)
1.04
(0.71-1.53)
Intermediate 3.29 **(1.80-6.00)
2.97 **
(1.89-4.68)
2.86 **
(1.94-4.22)
Late 1.63(0.56-4.80)
2.53 *
(1.26-5.07)
2.54 *
(1.41-4.56)
Persistent 1.63(0.66-4.00)
2.39 *
(1.21-4.70)
2.02 *
(1.17-3.49)
Tucson
Never 0.70 *(0.49-0.99)
0.76
(0.56-1.03)
0.73 *
(0.57-0.94)
Transient Early 1.10(0.67-1.81)
1.06
(0.70-1.61)
1.14
(0.83-1.58)
Late-Onset 1.63(0.56-4.80)
2.53 *
(1.26-5.07)
2.54 *
(1.41-4.56)
Persistent 2.57 
*
(1.45-4.56)
3.17 **
(2.04-4.91)
2.58 **
(1.79-3.72)
*p<0.05
**p<0.001
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